IMARC Group, a leading market research company, has recently releases report titled “Anti-Obesity Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global anti-obesity drugs market share, size, growth, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Industry Overview of Anti-Obesity Drugs

Anti-obesity drugs are pharmacological agents designed to aid in weight management for individuals affected by obesity. They are prescribed when traditional weight loss methods prove insufficient for patients with a high body mass index (BMI) and related health issues. They help reduce fat absorption, suppress appetite, and increase metabolism. They aid in controlling calorie intake by preventing cravings for sweets and fatty, salty, and high-calorie food products and enable individuals to lead more active lifestyles. Besides this, as they help regulate blood sugar levels, cholesterol levels, and blood pressure, the demand for anti-obesity drugs is increasing across the globe.

How Big Is the Anti-Obesity Drugs Market?

The global anti-obesity drugs market size reached US$ 2.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.0 Billion by 2028, exhibiting a growth rate (CAGR) of 11.7% during 2023-2028.

Request Sample Copy of This Report: https://www.imarcgroup.com/anti-obesity-drugs-market/requestsample

What are the growth prospects and trends in the anti-obesity drugs industry?

There is a rise in the prevalence of obesity globally due to sedentary lifestyles, unhealthy diets, and lack of physical activity. This rising burden of obesity and its associated health risks is catalyzing the demand for effective weight management solutions, including anti-obesity drugs.

Additionally, the increasing awareness among the masses about the severity of is encouraging manufacturers to introduce more effective and safer drugs. Apart from this, the expansion of healthcare infrastructure and increasing investment in research and development (R&D) activities in the pharmaceutical sector are contributing to market growth.

Moreover, the trend toward personalized medicine and the development of drugs targeted at specific genetic profiles are expected to propel market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

Breakup by Drug Class:

  • Peripherally Acting Drugs
  • Centrally Acting Drugs

Breakup by Drug Type:

Breakup by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Breakup by Region:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

Who are the key players operating in the industry?

The report covers the major market players including:

Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Gelesis, GlaxoSmithKline plc, Merck & Co. Inc., Norgine B.V., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Vivus LLC.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Email: sales@imarcgroup.com

Follow us on Twitter: @imarcglobal

LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/